Strong H1 2026 results featured 29% EPS growth, margin expansion, and robust cash flow, despite moderate revenue growth and softness in biopharma. Strategic portfolio focus, digitalization, and network integration are driving efficiency, with mid-term growth and margin objectives reaffirmed.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.